key: cord-0971072-pghlgsq6 authors: Bernas, Stefanie N.; Baldauf, Henning; Wendler, Sarah; Heidenreich, Falk; Lange, Vinzenz; Hofmann, Jan A.; Sauter, Jürgen; Schmidt, Alexander H.; Schetelig, Johannes title: CCR5Δ32 mutations do not determine COVID-19 disease course date: 2021-03-02 journal: Int J Infect Dis DOI: 10.1016/j.ijid.2021.02.108 sha: 83789d40a9ce2097fd9a03837246f54ce6fd3e22 doc_id: 971072 cord_uid: pghlgsq6 Objectives To determine the impact of the 32bp deletion (CCR5Δ32) in the coding region of the C-C chemokine receptor 5 (CCR5) on the risk of contracting SARS-CoV-2 and severe COVID-19. Methods Cross-sectional study among stem cell donors registered with DKMS in Germany. Genetic information was linked to self-reported COVID-19 outcome data. Multivariable regression models were fitted to determine the risk of contracting SARS-CoV-2, severe respiratory tract infection (RTI) and respiratory hospitalization. Results CCR5 information was available for 110,544 donors who were tested at least once for SARS-CoV-2. 5,536 participants with CCR5 information reported SARS-CoV-2 infections. For 4,758 donors the COVID-19 disease course was fully evaluable, 498 reported no symptoms, 1,227 described symptoms of severe respiratory tract infections, and 164 of these individuals required respiratory hospitalization. The distribution of CCR5Δ32 genotypes (homozygous wild-type vs. CCR5Δ32 present) did not differ significantly between individuals with or without SARS-CoV-2 infections (OR 0.96, 95%-CI 0.89-1.03, p = 0.21) nor between individuals with or without symptomatic infections (OR 1.13, 95%-CI 0.88-1.45, p = 0.32), severe RTI (OR 1.03, 955-CI 0.88-1.22, p = 0.68) or respiratory hospitalizations (OR 1.16, 95%-CI 0.79-1.69, p = 0.45). Conclusions Our data implicate that CCR5Δ32 mutations do not determine the risk of SARS-CoV-2 infections nor the disease course. Trial registration We registered the study with the German Center for Infection Research (https://dzif.clinicalsite.org/de/cat/2099/trial/4361). The 32bp deletion (CCR5Δ32) in the coding region of the C-C chemokine receptor 5 (CCR5) is a common variant and diminishes CCR5 expression on the cell surface. CCR5Δ32 carriers show resistance to infections with human immunodeficiency virus type-1 (HIV-1) explained by the fact that CCR5 represents one of two co-receptors for HIV-1 (Benkirane et al., 1997) . In contrast, fatal courses of influenza (Falcon et al., 2015) and West Nile virus (Lim et al., 2008) infections have been linked to an impaired effector cell recruitment in CCR5Δ32 carriers. Regarding SARS-CoV-2, the role of the receptor remains elusive. The CCR5 gene is located at 3p21.31, a gene cluster region that has been associated with severe COVID-19 courses (Severe Covid-19 GWAS Group et al., 2020) . Increased risk of infection and mortality correlated with the prevalence of the CCR5Δ32 allele in one population study (Panda et al., 2020) . On the contrary, leronlimab, a CCR5 blocking antibody, showed potential clinical benefit in individual patients with severe COVID-19 implying that CCR5 might mediate immune dysregulation caused by the SARS-CoV-2 infection (Patterson et al., 2020) . Two ongoing randomized clinical trials evaluate leronlimab in patients with COVID-19 (NCT04343651, NCT04347239). Here, we present results from a cross-sectional study conducted among 18-to 61- year-old stem cell donors registered with DKMS in Germany. The study aimed at identifying immunogenetic risk factors for severe SARS-CoV-2 infections (Schetelig et al., 2020) . All participants provided informed consent on study participation. Medical data on SARS-CoV-2 tests, risk factors, symptoms, and treatment were collected with a standardized health questionnaire. The medical information was linked to existing data on CCR5Δ32 deletions determined at donor registration (Solloch et al., 2017) . Donors who are homozygous for this mutation are preferably selected for patients with HIV infections (Hütter et al., 2009 ). In total, CCR5 information was available for 110,544 tested study participants. Of these, 22,203 (20.1%) had a CCR5Δ32 deletion ( Figure 1 ). The prevalence of Of those, 498 reported asymptomatic COVID-19 courses, 1,227 described symptoms compatible with severe RTI which required respiratory hospitalization in 164 cases ( Figure 1 ). This distribution of asymptomatic and symptomatic cases was in line with national surveillance data (Robert Koch Institute, 2020). The genotype distribution of CCR5Δ32 did not differ significantly between infected and non-infected individuals (homozygous wild-type vs. CCR5Δ32 present OR 0.96, 95%-CI 0.89-1.03, p=0.21). Also, no significant differences for the prevalence of CCR5Δ32 were found among patients with different clinical courses: symptomatic infections OR 1.13, 95%-CI 0.88-1.45, p=0.32; severe RTI OR 1.03, 95%-CI 0.88-1.22, p=0.68; respiratory hospitalizations OR 1.16, 95%-CI 0.79-1.69, p=0.45 (Table J o u r n a l P r e -p r o o f 1). Since the distribution of asymptomatic versus symptomatic cases largely depends on the testing strategy, symptomatic cases might be over-represented in our data which were collected during a period when mainly individuals were tested who showed symptoms suggestive of SARS-CoV-2 infection. Yet, our analysis did not even show a trend for a different distribution of CCR5Δ32 among asymptomatic and symptomatic cases (Figure 1 ). It is therefore highly unlikely that under-representation of asymptomatic cases biased our results. We did not find a statistically significant difference although the study was powered sufficiently. For example, to detect a change of the risk for respiratory hospitalization by factor 2 for individuals with a heterozygous CCR5Δ32 deletion the study had a power of 85%. The power was close to 100% for a comparable change of the risk of infection, symptomatic infection or severe RTI at the 5% significance level respectively. As a consequence, our data do not support the previously suggested association between CCR5Δ32 and the risk of contracting SARS-CoV-2 or the risk of severe COVID-19 courses (Panda et al., 2020) . It is unclear to what extent the effects of CCR5Δ32 deletion and a transient druginduced CCR5 blockade as described by Patterson (Patterson et al., 2020) are comparable; therefore, our results should not be interpreted as an indicator that leronlimab will not be effective. Hence, our data may trigger further research aiming at a better understanding of the impact of heterozygous or homozygous CCR5Δ32 Mechanism of transdominant inhibition of CCR5-mediated HIV-1 infection by ccr5delta32 CCR5 deficiency predisposes to fatal outcome in influenza virus infection Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation Genetic deficiency of chemokine receptor CCR5 is a strong risk factor for symptomatic West Nile virus infection: a meta-analysis of 4 cohorts in the US epidemic CCR5 Δ32 minorallele is associated with susceptibility to SARS-CoV-2 infection and death: An epidemiological investigation CCR5 inhibition in critical COVID-19 patients decreases inflammatory cytokines, increases CD8 T-cells, and decreases SARS-CoV2 RNA in plasma by day 14 Situation report of the Robert Koch Institute COVID-19 Severity of Respiratory Infections due to SARS-CoV-2 in Working Population: Age and Body Mass Index Outweigh ABO Blood Group Severe Covid-19 GWAS Group Genomewide Association Study of Severe Covid-19 with Respiratory Failure Frequencies of gene variant CCR5-Δ32 in 87 countries based on next-generation sequencing of 1.3 million individuals sampled from 3 national DKMS donor centers We are very grateful to all registered DKMS donors who participated in this study. In addition, we would like to acknowledge the dedicated support of many of our colleagues in different departments. Further, we would like to acknowledge a research grant from BMBF (reference number 01KI20177) which in parts facilitated this study.J o u r n a l P r e -p r o o f Research (BMBF) supported the study by a research grant (COVID-19 call (202), reference number 01KI20177). The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. The authors declare that there is no conflict of interest. The responsible Institutional Review Board of the Technische Universität Dresden (IRB00001473) approved the study. The study was conducted in compliance with the principles of the Declaration of Helsinki. All participants provided informed consent.